Skip to content
Try Mental Wellness – Lifestyle
Author:
Eton Pharmaceuticals
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
May 20, 2026
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
May 14, 2026
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
May 12, 2026
←
Previous Page
1
2